Mangalam Drugs And Organics Ltd.
Snapshot View

189.65 +1.25 ▲0.7%

03 August 2021, 04:00:00 P.M.
Volume: 45,909

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.mangalamdrugs.com
Financial Indicators
Market Cap 300.18 Cr.
Earnings per share (EPS) 17.67 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 10.73 Trailing Twelve Months Ending 2021-03
Industry PE 32.95 Trailing Twelve Months Ending 2021-03
Book Value / Share 82.74 Trailing Twelve Months Ending 2021-03
Price to Book Value 2.29 Calculated using Price: 189.65
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 1.58 Cr. 15,828,248 Shares
FaceValue 10
Company Profile

Mangalam Drugs & Organics Limited (Mangalam) is a part of the MangalamGroup promoted by Dhoot family in 1972 as Advent Pharma PrivateLimited with a view to set up a plant for manufacture of organic andinorganic chemicals. Mangalam Drugs & Organics commmenced its business in 1977.

The company manufactures chemicals such as API perfumery, disperse dye intermediates, bulk drugs and bulk drugs intermediates at VAPI-Gujarat State. It has a multi-product manufacturing facility and a in-house Research and Development (R&D) Base.

The Company has a diversified product range having synergies in operations and substantial economies of scale. It is amongst the top three manufacturers in India in almost all the products that it manufactures.

Today Mangalam Drugs & Organics enjoys a very strong brand name in the domestic market. It has over two decades of experience in the industry with a very wide and satisfied customer base.

The company has a state of art multi-product manufacturing facilitiesat Vapi in Gujarat and Sangamner in Maharashtra for production of bulkdrugs perfumery chemicals inorganic chemicals and disperse dyesintermediaries with a strong in-house Research and Development base.

Product range of the company includes:

Active Pharma Ingredients (API)

  • Anti Malarial
  • Analgesic / Anti Inflammatory
  • Diuretic
  • Anti Hypertensive
  • Anti Convulsant

API Under Development

  • Intermediates
  • Antiurolithic

Prefumery / Specialty Chemicals

  • Phenyl Ethyl Alcohol
  • Phenyl Ethyl Methyl Ether
  • Phenyl Ethyl Acetate

Disperse Dye Intermediates

  • Meta Nitro Aniline (Mna)(99-09-2)
  • Meta Amino Propionilide (MAP)
  • Meta Amino Acetanilide (MAA) (162-28-3)
  • Para Amino Acetanilide (PAA) 122-80-5)
  • Para Amino Propionilide (PAP) (59690-89-0)
  • N-Cyano Ethyl Aniline (1075-76-9)
  • N,N-BIS (2-Hydroxy Ethyl) Meta Chloro Aniline (Mangalam-1) (92-00-2)
  • N,N-BIS (2-Acetoxy Ethyl) Meta Chloro Aniline (Mangalam -1A) (26692-46-6) etc.

Achievements/ recognition:

  • Awarded the ISO 9001:2000 Management System Certificate from DNV for Design Development, Manufacture and supply of Bulk Drugs, and Dyes Intermediates.
  • Received the WHO GMP Certificate for its Bulk Drug manufacturing Plant

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+0.66%
1 Week
-0.68%
1 Month
+27.67%
3 Month
+35.13%
6 Month
+52.15%
1 Year
+179.10%
2 Year
+456.98%
5 Year
+14.90%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 1.68 -36.69 -12.28 23.36 38.91 32.11 20.99 -8.05 8.27
Return on Capital Employed (%) 12.04 -6.85 5.86 15.69 29.14 30.18 25.35 1.76 10.66
Return on Assets (%) 0.54 -9.97 -2.53 4.16 9.73 12.76 9.56 -3.67 3.73

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 38 26 23 29 62 86 104 96 104
Non Curr. Liab. 28 45 41 41 25 26 23 25 17
Curr. Liab. 55 43 61 99 73 78 100 91 109
Minority Int.
Equity & Liab. 122 115 125 170 160 190 227 211 231
Non Curr. Assets 59 57 54 54 60 94 104 106 111
Curr. Assets 63 57 71 116 100 96 123 105 119
Misc. Exp. not W/O
Total Assets 122 115 125 170 160 190 227 211 231

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 153 125 123 221 295 303 279 228 282
Other Income 1 2 0 0 0 0 1 0 1
Total Income 154 127 123 221 295 303 280 228 284
Total Expenditure -139 -130 -113 -200 -258 -257 -233 -218 -259
PBIDT 15 -3 10 20 38 46 48 10 25
Interest -10 -10 -10 -10 -9 -10 -12 -9 -10
Depreciation -4 -4 -4 -4 -4 -5 -7 -7 -8
Taxation -1 5 1 0 -8 -9 -9 -2 2
Exceptional Items
PAT 1 -12 -3 6 16 22 20 -8 8

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 7 -1 7 14 22 43 25 22 31
Cash Fr. Inv. -6 -2 -2 -4 -11 -39 -16 -9 -7
Cash Fr. Finan. 0 2 -5 -10 -11 -3 -9 -11 -23
Net Change 0 -1 0 1 0 0 0 1 0
Cash & Cash Eqvt 1 0 0 1 1 1 0 1 2

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 50.53 50.53 50.53 50.53 50.53 50.53 50.53 50.53 50.53
Public 49.47 49.47 49.47 49.47 49.47 49.47 49.47 49.47 49.47
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 61.89 61.89 33.57 33.57 33.57 33.57

Announcements View Details

Tue, 03 Aug 2021
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on August 02 2021 for Aditya Dhoot
Tue, 03 Aug 2021
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on August 02 2021 for Ajay Dhoot
Tue, 03 Aug 2021
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on August 02 2021 for Shree Kishoriju Trading and Investment Pvt Ltd

Technical Scans View Details

Tue, 03 Aug 2021
Close Within 52 Week High Zone Close Within 52 Week High Zone
William %R Crossed -20 From Below William %R Crossed -20 From Below
CCI Overbought Zone CCI Overbought Zone
RSI Overbought Zone RSI Overbought Zone
Mon, 02 Aug 2021
Close Crossing Last Month Close From Below Close Crossing Last Month Close From Below

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 190,711.14 794.85 +2.6%
Divi's Laboratories Ltd. 132,945.34 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. 78,541.95 4,721.20 +0.4%
Cipla Ltd. 74,795.92 927.25 +0.6%
Cadila Healthcare Ltd. 60,600.44 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. 58,835.96 4,076.05 +0.7%
Piramal Enterprises Ltd. 56,942.27 2,507.65 +0.7%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 31.77 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2021-03 67.00 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.21 4,721.20 +0.4%
Cipla Ltd. Consolidated 2021-03 31.10 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 28.40 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 391.30 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 42.74 2,507.65 +0.7%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 3.98 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2021-03 14.30 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.39 4,721.20 +0.4%
Cipla Ltd. Consolidated 2021-03 4.09 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 4.66 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.80 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 1.66 2,507.65 +0.7%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 0.18 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 2,507.65 +0.7%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 10.09 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 2,507.65 +0.7%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 12.53 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 10.03 2,507.65 +0.7%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 19,159.59 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 2,507.65 +0.7%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 2,401.30 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 2,507.65 +0.7%